B of A Securities Initiates Coverage On Haemonetics with Neutral Rating, Announces Price Target of $85
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has initiated coverage on Haemonetics with a Neutral rating and set a price target of $85.
September 11, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities has initiated coverage on Haemonetics with a Neutral rating and a price target of $85, indicating a balanced view on the stock's potential.
The Neutral rating suggests that the analyst does not expect significant upside or downside in the short term. The price target of $85 provides a benchmark for investors, but the neutral stance indicates a balanced view on the stock's potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100